The International Journal of Neuropsychopharmacology
October 21, 2022
James J Gattuso, Daniel Perkins, Simon Ruffell et al.
233 citations
Abstract Psychedelics are a unique class of drug that commonly produce vivid hallucinations as well as profound psychological and mystical experiences. A grouping of interconnected brain regions characterized by increased temporal coherence at rest have been termed the Default Mode Network (DMN). The DMN has been the focus of numerous studies assessing its role in self-referencing, mind...
October 19, 2022
Stefan Baumann, Robin Carhart-Harris, David Nutt et al.
2 citations
preprint
Microdosing is the practice of regularly using very low doses of psychedelic drugs. Anecdotal reports suggest that it may enhance well-being, creativity and cognition. Here, we use data from a self-blinding microdose trial, a large (n=240) placebo-controlled citizen science trial of microdosing to investigate whether tolerance develops during microdosing. We conceptualized tolerance as the...
Neuropharmacology
October 14, 2022
Ian G Campbell, Ioanna A. Vamvakopoulou, Kelly A.d. Narine et al.
97 citations
The pharmacological mechanisms of mescaline are similar to those of other classical psychedelics, like psilocybin and lysergic acid diethylamide (LSD). Mescaline appears to be safe to consume, with most intoxications being mild and easily treatable. Improvement in mental well-being and its ability to overcome alcoholism render mescaline potentially beneficial in clinical settings. This article...
Journal of Psychoactive Drugs
October 11, 2022
Jeremy Weleff, Teddy J. Akiki, Brian S. Barnett
11 citations
Following a decades long period of investigational dormancy, there is renewed interest in employing psychedelics as psychiatric treatments. The academic journals, institutions, and countries that have helped sustain clinical psychedelic research and the evolution of the literature on clinical studies of psychedelics have only recently begun to be investigated. To expand upon this work, we...
October 10, 2022
Malcolm Hopwood
Therapy is turning to drugs previously known for being illicit party substances. But there’s no reason to abandon proper trials. A range of new therapies for mental illness were previously considered unthinkable — party drugs including ketamine, medicinal cannabis and psychedelics like MDMA, psilocybin and DMT. With mental health disorders a growing cause of disability […]
Indian Journal of Forensic Medicine & Toxicology
October 10, 2022
Merlin Kirubakarababu, Arputharaj Samson Nesaraj
1 citation
Certain species of the mushrooms contain the Indole Alkaloids such as Psilocybin and Psilocin which exhibit the psychedelic property. These types of mushrooms can be identified by their unique property known as the blue bruising. These alkaloid compounds may cause the hallucinations and other symptoms. The psilocybin and Psilocin are synthesized from the amino acid Tryptophan and resemble the...
Journal of Psychoactive Drugs
October 5, 2022
Annie M. Mccartney, Hugh McGovern, Alexander de Foe
33 citations
Research on the therapeutic potential of psychedelic substances is expanding. A limitation within this field is the unpredictability of individual responses to psychedelics. Better understanding of factors predicting psychedelic experience is essential to clinical progress and wider harm reduction frameworks. Ketamine, MDMA, LSD and psilocybin were selected for comparison due to their promising...
Frontiers in Psychiatry
October 3, 2022
Jordi Camarasa, Pol Puigseslloses, Edurne Urquizu et al.
5 citations
The utility of classical drugs used to treat psychiatric disorders (e.g., antidepressants, anxiolytics) is often limited by issues of lack of efficacy, delayed onset of action or side effects. Psychoactive substances have a long history of being used as tools to alter consciousness and as a gateway to approach the unknown and the divinities. These substances were initially obtained from plants...
International Journal of Drug Policy
October 2022
Adam W. Levin, Paul Nagib, Selina Deiparine et al.
Evidence points to an incongruence between international drug policy and expert opinion about safety, abuse potential, and therapeutic potential of specific drugs. However, no prior studies have directly explored psychiatrists' attitudes about the current drug schedule. Therefore, we examined whether American psychiatrists' perceptions of four psychoactive drugs differed from those indicated by...
Drug and Alcohol Dependence
October 1, 2022
Otto Simonsson, Simon B. Goldberg, Richard Chambers et al.
16 citations
Previous studies have reported links between classic psychedelic use and seizures, but little remains known about prevalence and potential risk factors of classic psychedelic-related seizures. Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N = 2822), this study examined the prevalence and potential risk factors of classic psychedelic-related...